TEST:

TeloViewSMM test

"Telo Genomics Corp...is pleased to announce that its application to the IPON program (Intellectual Property Ontario) was approved...The most recent patent applications filed by Telo support intellectual property protection of its flagship product for smoldering multiple myeloma TeloViewSMM."

"Telo Genomics....announce that it has amended its agreement with Mayo Clinic, Rochester, Minnesota, US. The amendment is an extension of the Telo Genomics relationship with Mayo Clinic to include their participation in Telo’s Physician Experience Program SMART, using the Company’s TeloViewSMM prognostic test for smoldering multiple myeloma (SMM) patients. SMM is a precursor to active multiple myeloma."

"Telo Genomics Corp...is pleased to announce that it has presented the most recent performance results of its TeloViewSMM prognostic test for smoldering multiple myeloma (SMM) patients at the recent International Myeloma Society (IMS) 2024 annual meeting 2024 in Brazil."

"Telo Genomics Corp...is pleased to announce that the College of American Pathologists (CAP) has recently accepted Telo Genomics’ submission to add Telo’s test for smoldering multiple myeloma (SMM), TeloViewSMM, as a Laboratory Developed Test (LDT) on Telo’s-CAP approved menu of clinical tests."